Merck & Co Inc
NYSE:MRK

Watchlist Manager
Merck & Co Inc Logo
Merck & Co Inc
NYSE:MRK
Watchlist
Price: 106.9 USD -0.95%
Market Cap: $265.3B

Relative Value

The Relative Value of one MRK stock under the Base Case scenario is hidden USD. Compared to the current market price of 106.9 USD, Merck & Co Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MRK Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

MRK Competitors Multiples
Merck & Co Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Merck & Co Inc
NYSE:MRK
265.4B USD 4.1 14 9.9 11.8
US
Eli Lilly and Co
NYSE:LLY
954.9B USD 16.3 52.6 35.3 37.9
US
Johnson & Johnson
NYSE:JNJ
546.2B USD 5.8 20.4 14.3 17.5
CH
Roche Holding AG
SIX:ROG
269.6B CHF 4.5 29.4 12.5 14.6
UK
AstraZeneca PLC
LSE:AZN
208B GBP 4.9 30.2 19.7 28.8
CH
Novartis AG
SIX:NOVN
217.7B CHF 4.9 19.2 15.4 19.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.2 16 11.1 12.9
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
147.6B USD 2.3 15 7.6 10.4
FR
Sanofi SA
PAR:SAN
93.9B EUR 1.4 6.9 6.3 6.3
US
Bristol-Myers Squibb Co
NYSE:BMY
111.6B USD 2.3 18.4 6.6 8.7
P/E Multiple
Earnings Growth PEG
US
Merck & Co Inc
NYSE:MRK
Average P/E: 22.2
14
14%
1
US
Eli Lilly and Co
NYSE:LLY
52.6
54%
1
US
Johnson & Johnson
NYSE:JNJ
20.4
6%
3.4
CH
Roche Holding AG
SIX:ROG
29.4
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.2
38%
0.8
CH
Novartis AG
SIX:NOVN
19.2
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
16
2%
8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
15
27%
0.6
FR
Sanofi SA
PAR:SAN
6.9
25%
0.3
US
Bristol-Myers Squibb Co
NYSE:BMY
18.4
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Merck & Co Inc
NYSE:MRK
Average EV/EBITDA: 44
9.9
6%
1.7
US
Eli Lilly and Co
NYSE:LLY
35.3
34%
1
US
Johnson & Johnson
NYSE:JNJ
14.3
2%
7.1
CH
Roche Holding AG
SIX:ROG
12.5
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
19.7
10%
2
CH
Novartis AG
SIX:NOVN
15.4
6%
2.6
DK
Novo Nordisk A/S
CSE:NOVO B
11.1
1%
11.1
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
0%
N/A
FR
Sanofi SA
PAR:SAN
6.3
8%
0.8
US
Bristol-Myers Squibb Co
NYSE:BMY
6.6
-9%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Merck & Co Inc
NYSE:MRK
Average EV/EBIT: 94
11.8
8%
1.5
US
Eli Lilly and Co
NYSE:LLY
37.9
37%
1
US
Johnson & Johnson
NYSE:JNJ
17.5
6%
2.9
CH
Roche Holding AG
SIX:ROG
14.6
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
28.8
23%
1.3
CH
Novartis AG
SIX:NOVN
19.9
12%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
12.9
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
7%
1.5
FR
Sanofi SA
PAR:SAN
6.3
15%
0.4
US
Bristol-Myers Squibb Co
NYSE:BMY
8.7
10%
0.9